Literature DB >> 16684754

Defining a future for fee-for-service Medicare.

Susan Bartlett Foote1, Gwen Wagstrom Halaas.   

Abstract

The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) provides economic incentives that favor health plans over traditional fee-for-service (FFS) Medicare. This reflects an ideological preference for private plans rather than government-administered pricing and recognition that private plans can use tools effectively to improve quality. However, enrollment projections indicate that FFS will continue to attract the majority of beneficiaries for years to come. We argue that MMA's contractor reform provisions create the opportunity to build critical FFS infrastructure, and contractors have the potential to encourage quality and manage utilization to compete with private plans in a modernized Medicare.

Mesh:

Year:  2006        PMID: 16684754     DOI: 10.1377/hlthaff.25.3.864

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  3 in total

1.  Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans.

Authors:  Salomeh Keyhani; Joseph S Ross; Paul Hebert; Cornelia Dellenbaugh; Joan D Penrod; Albert L Siu
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

2.  Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study.

Authors:  Sophia L Johnson; Christie M Bartels; Mari Palta; Carolyn T Thorpe; Jennifer M Weiss; Maureen A Smith
Journal:  BMJ Open       Date:  2015-09-07       Impact factor: 2.692

3.  Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study.

Authors:  Sophia L Johnson; Mari Palta; Christie M Bartels; Carolyn T Thorpe; Jennifer M Weiss; Maureen A Smith
Journal:  BMC Pharmacol Toxicol       Date:  2015-12-08       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.